Back to Search Start Over

Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19.

Authors :
Zoodsma M
de Nooijer AH
Grondman I
Gupta MK
Bonifacius A
Koeken VACM
Kooistra E
Kilic G
Bulut O
Gödecke N
Janssen N
Kox M
Domínguez-Andrés J
van Gammeren AJ
Ermens AAM
van der Ven AJAM
Pickkers P
Blasczyk R
Behrens GMN
van de Veerdonk FL
Joosten LAB
Xu CJ
Eiz-Vesper B
Netea MG
Li Y
Source :
Frontiers in immunology [Front Immunol] 2022 Nov 03; Vol. 13, pp. 1027122. Date of Electronic Publication: 2022 Nov 03 (Print Publication: 2022).
Publication Year :
2022

Abstract

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic is caused by the highly infectious Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). There is an urgent need for biomarkers that will help in better stratification of patients and contribute to personalized treatments. We performed targeted proteomics using the Olink platform and systematically investigated protein concentrations in 350 hospitalized COVID-19 patients, 186 post-COVID-19 individuals, and 61 healthy individuals from 3 independent cohorts. Results revealed a signature of acute SARS-CoV-2 infection, which is represented by inflammatory biomarkers, chemokines and complement-related factors. Furthermore, the circulating proteome is still significantly affected in post-COVID-19 samples several weeks after infection. Post-COVID-19 individuals are characterized by upregulation of mediators of the tumor necrosis (TNF)-α signaling pathways and proteins related to transforming growth factor (TGF)-ß. In addition, the circulating proteome is able to differentiate between patients with different COVID-19 disease severities, and is associated with the time after infection. These results provide important insights into changes induced by SARS-CoV-2 infection at the proteomic level by integrating several cohorts to obtain a large disease spectrum, including variation in disease severity and time after infection. These findings could guide the development of host-directed therapy in COVID-19.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Zoodsma, de Nooijer, Grondman, Gupta, Bonifacius, Koeken, Kooistra, Kilic, Bulut, Gödecke, Janssen, Kox, Domínguez-Andrés, van Gammeren, Ermens, van der Ven, Pickkers, Blasczyk, Behrens, van de Veerdonk, Joosten, Xu, Eiz-Vesper, Netea and Li.)

Details

Language :
English
ISSN :
1664-3224
Volume :
13
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
36405747
Full Text :
https://doi.org/10.3389/fimmu.2022.1027122